key: cord-0749556-wz1zf1a2
authors: Alhalabi, Marouf; Eddin, Kamal Alaa; Ali, Fadwa; Abbas, Ahmad
title: SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis: A case report
date: 2022-01-28
journal: Medicine (Baltimore)
DOI: 10.1097/md.0000000000028722
sha: ec5b4e4218045e7eabdce750b9802ce46776204e
doc_id: 749556
cord_uid: wz1zf1a2

RATIONALE: The ongoing coronavirus pandemic has caused severe acute respiratory syndrome, posing a significant challenge for patients receiving immunotherapy for immune-mediated inflammatory diseases. As of January 2022, immunosuppressants such as tumor necrosis factor inhibitors (anti-TNFα) and azathioprine are inadvisable for an infectious disease caused by the SARS-CoV-2 virus (COVID-19). We continued infliximab as a second induction dose nine days after the onset of COVID-19 symptoms in a patient with acute severe ulcerative colitis. PATIENT CONCERNS: We report the case of a 34-year-old male with 6 to 8 times bloody diarrhea, fever, and cramping abdominal pain. Ulcerative colitis was diagnosed 6 months earlier and treated with mesalamine 80 mg/kg/day and azathioprine 2.5 mg/kg/day. The patient had never undergone surgery before. Sigmoidoscopy revealed multiple ulcerations and spontaneous bleeding, and the colon samples tested negative for cytomegalovirus and Clostridium difficile. However, intravenous corticosteroids did not induce remission. A nasopharyngeal swab tested positive for SARS-CoV-2. DIAGNOSIS: Acute severe ulcerative colitis and SARS-CoV-2 (COVID-19) pneumonia. INTERVENTIONS: The second loading dose of infliximab was administered nine days after the diagnosis of COVID-19. OUTCOME: The patient completed infliximab induction at a dose of 5 mg/kg at weeks 0, 2, and 6, with no complications. LESSONS: It is unclear whether anti-TNF-α treatment improves or deteriorates COVID-19 patient outcomes, and this case demonstrates that infliximab can be used safely. Current guidelines make a weak recommendation to avoid using anti-TNFα agents in the presence of acute COVID-19 infection. There is an urgent need for research on biologics therapy.

The an infectious disease caused by the SARS-CoV-2 virus (COVID-19) outbreak in December 2019 spread rapidly and caused severe lung damage that can lead to death. [1, 2] New cases continue to emerge around the world, during September 2021 Syria experienced a severe wave, with a substantial increase in cases posing a significant threat to public health. [3] According to Ferm et al, COVID-19 infection can cause a variety of symptoms, including gastrointestinal manifestations such as diarrhea (19.8%), nausea (16.6%), loss of appetite (11.8%), vomiting (10.2%), and loss of taste (2.4%). [4] Where all or some of these symptoms are shared with many diseases, including inflammatory bowel diseases, and when these diseases are present, it is difficult to diagnose COVID-19 infection. Higher serum levels of proinflammatory cytokines (TNFa, IL-1, IL-6, and IL-8) in COVID-19 patients cause cytokine storms, which trigger a series of immune responses that damage the corresponding organs. [5] Attempts to treat or relieve infection symptoms rely on suppressing the cytokine storm; dexamethasone, for instance, inhibits severe cytokine storm or the hyper-inflammatory phase in hospitalized COVID-19 patients, [6] [7] [8] whereas Neurath argued for an necrosis factor antagonists (anti-TNFa) protective effect in severe COVID-19 patients, but it was not used in COVID-19 treatment, [9] and both corticosteroids and anti-TNF are essential in the treatment of inflammatory bowel disease. [10] [11] [12] We described infliximab-treated acute severe ulcerative colitis (ASUC) with SARS-CoV-2 (COVID-19) pneumonia. Nine days after the onset of symptoms, we administered a second loading dose of infliximab, according to the protocol. The patient completed infliximab induction at 5 mg/kg doses at weeks 0, 2, and 6, with no complications.

We admitted a 34-year-old man with a history of bloody diarrhea 6 to 8 times a day with a fever of 38.9 and cramping abdominal pain. The patient had a history of left-sided colitis, and the diagnosis was established 6 months ago without prior surgery. His past medication included azathioprine 1.5 to 2.5 mg/kg/ day, [10] [11] [12] and oral mesalamine 2 g/day. [10] [11] [12] [13] The patient's adherence to the previous medication was confirmed. On admission, tests revealed leukocytosis, an increase in C-reactive protein (CRP), and an increase in erythrocyte sedimentation rate. COVID-19 rapid antigen test results for IgM and IgG were negative. Stool studies, including ova and parasite microscopy, routine stool cultures, [14] Clostridium difficile toxin testing, and testing for Escherichia coli, Shigella, and Cryptosporidium, all returned negative results. Chest radiography, abdominal radiography, and abdominal ultrasonography findings were normal. Sigmoidoscopy revealed multiple ulcers with spontaneous bleeding extending to the left side of the colon Figure 1 , and colon biopsies were negative for cytomegalovirus and Clostridium difficile infections. The patient's Mayo score was 11 points. [15] We started with intravenous fluid and electrolyte replacement, hydrocortisone 100 mg 4 times daily, and lowmolecular-weight heparin were administered for thromboprophylaxis. [10] [11] [12] The patient did not respond to corticosteroids, and screening for infections as recommended before prescribing biological therapies returned negative results. Infliximab was started at a dose of 5 mg/kg. [10] [11] [12] The patient experienced fever, sore throat, dry cough, dyspnea 5 days after starting infliximab, which continued at a frequency of 4 times per day, while bloody diarrhea stopped, and the patient's examination was normal. We performed microbiological studies on a non-invasive respiratory sample, [16] besides, a nasopharyngeal swab was used for reverse transcription-polymerase chain reaction to detect SARS-CoV-2 (COVID- 19) , which was positive. The patient continued lowmolecular-weight heparin (for a hospitalized ASUC), acetaminophen, vitamin D, vitamin C, and zinc intake. [17, 18] Figure 2 shows a chest computed tomography scan performed three days after the onset of symptoms. The patient had moderate illness, and the symptoms began to improve. [19] On the twelfth day, the patient's fever and shortness of breath disappeared. The patient still complained of diarrhea up to 4 times, without blood, and the partial Mayo score was 4 points. The patient received a second induction dose of infliximab nine days after the onset of COVID-19 symptoms. The patient completed infliximab induction at a dose of 5 mg/kg at weeks 0, 2, and 6, with no complications. Table 1 shows the patients' test results upon admission and discharge.

Ulcerative colitis is a chronic intestinal disease. It is critical to begin treatment as early as possible, which is known as the treatto-target management approach. [20, 21] Treatment objectives have been established to improve the outcomes. It entails determining an appropriate target, selecting initial therapy, measuring baseline disease characteristics, monitoring treatment progress, and optimizing therapy to achieve the treatment aim. [21] Endoscopic scores such as the Mayo score and the ulcerative colitis endoscopic index of severity, and biomarkers such as fecal calprotectin and CRP are the most important effective monitoring tools. [21, 22] Fecal calprotectin correlates well with endoscopic disease activity. It is important in a variety of clinical settings, including initial diagnosis, relapse, and response to treatment, whereas CRP correlates less well with clinical severity in ulcerative colitis, except for acute severe colitis. [15] Syrian current humanitarian crisis has been harmed chronic disease patients particularly in terms of medicine availability as many were unavailable, and difficulties in maintaining their presence. [23] [24] [25] It is common practice in Syria to evaluate UC patients with clinical scores and CRP levels. If there were signs of treatment failure, we performed a colonoscopy and fecal calprotectin. [15, 26] 5-ASA enemas, which are not available in Syria, were used to treat mild to moderate ulcerative colitis on the left side and were preferred over rectal steroids for induction of remission. [10] [11] [12] 27, 28] Immunosuppressive therapy such as steroids, azathioprine, and anti-TNFa play a significant role in treatment. [10] [11] [12] Anti-TNFa has the potential to activate opportunistic infections; [29] therefore, it is important to screen for its presence before starting biological treatment such as latent tuberculosis, [30, 31] and hepatitis B. [32] However, some opportunistic infections, such as cytomegalovirus, do not require scanning for its presence before starting treatment. [29, [33] [34] [35] Current guidelines recommend reverse transcription-polymerase chain reaction as a test for COVID-19 before an endoscopic procedure, [36, 37] and before initiating long-acting biologic therapy. [38] It has the highest sensitivity and specificity, but it is expensive and can take up to 24 hours to produce results, while rapid antigen tests are becoming more popular due to their low cost and near-instant results. [39] The COVID-19 pandemic is an ongoing global health crisis, causing progressive pneumonia and may be complicated by and multi-organ failure. [40, 41] There are conflicting views on the role of immunosuppressants in COVID-19. Some argue that immunosuppressive drugs have a negative effect on the disease's progression. [42] Others argue that immune modulators, both specific and non-specific, can inhibit cytokines and calm the cytokine storm. [43] This disparity could be attributed to the COVID-19, the patients, or the immunosuppressant used. Severe cases of COVID-19 that may lead to death are attributed to, cytokine release syndrome, which is characterized by elevated serum interleukin (IL-6, IL-8, IL-10, and TNFa) levels, cytokine release syndrome-induced macrophage activation syndrome, and hemophagocytic histiocytosis. [5, 9, [44] [45] [46] [47] Comorbidities, old age, and male sex are all risk factors for COVID-19 infection poor outcomes. [48, 49] Because of the potential interactions between the immune response associated with COVID-19 and dysfunctional immunity associated with inflammatory bowel disease, patients with both diseases may face unique challenges in their management. In ASUC, we rely on scores such as Mayo, partial Mayo, and Truelove and Witts to assess treatment response. [15] Those scores included parameters such as temperature, diarrhea frequency, and the results of laboratory tests such as CRP and erythrocyte sedimentation rate, which are related to COVID-19 infection. This adds another challenge for assessing and managing patients with ASUC and COVID-19. The treatment of patients with ASUC and COVID-19 is complicated. Current recommendations are to use lower doses of prednisone (20 mg/d) or budesonide and to avoid thiopurines, methotrexate, and tofacitinib, and postpone anti-TNF therapies, ustekinumab, and vedolizumab for 2 weeks while monitoring the development of COVID-19. This will aid in the search for the disappearance of IgM antibodies and the development of IgG antibodies. [50, 51] Although chest computed tomography scans aid in the diagnosis of infection, they also help in the assessment and management of patients. [52] [53] [54] According to Stallmach et al and Honore et al Infliximab may prevent COVID-19-induced cytokine storm syndrome and reduce mortality in critically ill COVID-19 patients. [55, 56] Two case reports have described the use of anti-TNF in the context of inflammatory bowel diseases and COVID-19 infection. Tursi et al reported a case of crohn's disease treated with adalimumab for 5 years. Adalimumab is administered at a dose every 2 weeks, and its scheduled dose is suspended when COVID-19 infection has been proven. [57] While Abdullah et al reported a case of an infliximab ulcerative colitis patient who achieved sustained clinical remission with infliximab and was infected with COVID-19. The patient did not require hospitalization and the clinical symptoms resolved completely within a week of onset, with no change in ulcerative colitis activity. The next dose of infliximab will be approximately 8 weeks later. [58] In our case, several factors influenced the decision to administer the second dose of infliximab, including the indication for infliximab as ASUC refractory to corticosteroids, and the first infliximab dose produced a significant response. It also had no negative effects on COVID-19 infection and infliximab antibodies formation as a result of intermittent treatment, and maintenance therapy is most likely the most effective strategy for optimizing treatment and avoiding immunogenicity. [59] What makes this case unique is that we used 2 doses of infliximab within 2 weeks to treat ASUC with COVID-19 pneumonia; the first dose was 5 days before the onset of COVID-19 symptoms, and the second was 9 days later. Neither dose resulted in serious complications, as the pulmonary symptoms subsided within a week. The patient completed infliximab induction at a dose of 5 mg/kg at weeks 0, 2, and 6, with no complications. Data on anti-TNFa effects in COVID-19 patients are limited, although current treatment guidelines advise against the use of anti-TNFa in patients with acute COVID-19 infection. These recommendations are weak as they are not based on clinical studies. This case demonstrates that infliximab can be safely used. However, further studies are needed to determine the factors involved in the selection of patients to continue biological treatment in association with acute COVID-19.

All authors have read and approved the manuscript on behalf of all contributors I will act and guarantor and will correspond with the journal from this point onward.

Conceptualization: Marouf Mouhammad Alhalabi.

A new coronavirus associated with human respiratory disease in China

Clinical characteristics of coronavirus disease 2019 in China

An interactive web-based dashboard to track COVID-19 in real time

Analysis of gastrointestinal and hepatic manifestations of SARS-CoV-2 infection in 892 patients in queens

Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China

Dexamethasone in hospitalized patients with Covid-19

Infectious diseases society of America guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19)

Dexamethasone to combat cytokine storm in COVID-19: clinical trials and preliminary evidence

COVID-19 and immunomodulation in IBD

ACG clinical guideline: ulcerative colitis in adults

Third European evidencebased consensus on diagnosis and management of ulcerative colitis. Part 2: current management

British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults

Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis

Diagnostic yield of stool culture and predictive factors for positive culture in patients with diarrheal illness

ECCO-ESGAR guideline for diagnostic assessment in IBD Part 2: IBD scores and general principles and technical aspects

Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the

COVID-19 Treatment Guidelines

Hospitalized Adults: Therapeutic Management

Treatment Guidelines

COVID-19 Treatment Guidelines

STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD

Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: a systematic review

The ulcerative colitis endoscopic index of severity more accurately reflects clinical outcomes and long-term prognosis than the mayo endoscopic score

Public health consequences after ten years of the Syrian crisis: a literature review

World Health Organization -Regional Office for the Eastern Mediterranean

Severe shortages in life-saving medicines inside Syria of major concern to WHO -Syrian Arab Republic

Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes

Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis

A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis

Opportunistic infections with anti-tumor necrosis factor-a therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials

Risk of tuberculosis in patients treated with TNF-a antagonists: a systematic review and meta-analysis of randomised controlled trials

Tuberculosis and anti-TNF-a treatment

Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management

Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease

Infliximab does not worsen outcomes during flare-ups associated with cytomegalovirus infection in patients with ulcerative colitis

Cytomegalovirus, inflammatory bowel disease, and anti-TNFa

COVID-19 polymerase chain reaction testing before endoscopy: an economic analysis

AGA institute rapid review and recommendations on the role of preprocedure SARS-CoV-2 testing and endoscopy

Infectious diseases society of America guidelines on the diagnosis of coronavirus disease 2019

COVID-19 rapid antigen test: role in screening prior to gastrointestinal endoscopy

Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study

Post-COVID-19 complications: multisystemic approach

Prior immunosuppressive therapy is associated with mortality in COVID-19 patients: a retrospective study of 835 patients

Pharmaco-immunomodulatory therapy in COVID-19

Cytokine release syndrome in severe COVID-19

SARS-CoV-2 infectionassociated hemophagocytic lymphohistiocytosis

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Evolving status of the 2019 novel coronavirus infection: proposal of conventional serologic assays for disease diagnosis and infection monitoring

Clinical outcomes of 402 patients with COVID-2019 from a single center in Wuhan

Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths

AGA clinical practice update on management of inflammatory bowel disease during the COVID-19 pandemic: expert commentary

British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic

The role of chest imaging in patient management during the COVID-19 pandemic: a multinational consensus statement from the fleischner society

Chest CT in COVID-19 at the ED: validation of the COVID-19 reporting and data system (CO-RADS) and CT severity score: a prospective, multicenter, observational study

The usefulness of chest CT imaging in patients with suspected or diagnosed COVID-19: a review of literature

Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider

Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series

COVID-19 infection in Crohn's disease under treatment with adalimumab

Mild COVID-19 symptoms in an infliximab-treated ulcerative colitis patient: can ongoing anti-TNF therapy protect against the viral hyperinflammatory response and avoid aggravated outcomes?

Immunogenicity of infliximab: how to handle the problem?

Medicine (2022) 101:4 www.md-journal